fbpx Femtonics - Products - Femtonics Femtonics - Homepage

Products

FEMTO3D Atlas

The FEMTO3D Atlas software:

  • our measurement control and analysis software suite powering the FEMTO3D Atlas,
  • supports a multitude of imaging workflows from fast planar imaging to patterned 3D photostimulation and simultaneous multicolor activity recording.

Find 3D scanning modes and other features on the Atlas Software product page.

 

FEMTOSmart

The FEMTOSmart software:

  • powers our conventional 2D two-photon microscopes,
  • offers streamlined simplicity for efficient, standardized data collection,
  • offers all the essential functions for conventional experimental scenarios, including:
    • fast planar and Z-stack recordings,
    • scanning along 2D trajectories,
    •  photostimulation,
  • a compact set of tools for data visualization and analysis,
  • hardware controls arranged in an ergonomically designed interface.

Analysis, programming tool, automation

  • Our microscopes can be extended by optional modules implementing specific measurement or analysis functions.
  • Extending or automating available acquisition control and analysis functions is possible by interfacing custom scripts to Atlas or FEMTOSmart microscopes.
FEMTO3D Atlas software
FEMTOSmart software
Contact us

Provided by

DNI-Gly*TFA

Technology Overview

Femtonics Chemistry designs and develops new caged neurotransmitters for frontier neuroscience research. The two main products are a glutamate derivative and a GABA (gamma-amino-butyric acid) derivative. These dinitro-indoline-masked forms of glutamate and GABA release the bioactive forms of the two neurotransmitters more rapidly than other, commercially available versions of these compounds. They were developed to have high-quantum yield, requiring less irradiation for release, so their effective concentrations are lower than that of other caging scaffolds. DNI-Glu and iDMPO-DNI-GABA are compounds developed in-house, only available from Femtonics; in addition, iDMPO-DNI-GABA is the only commercially available caged GABA compound.

Features
  • Name: 2-amino-1-(4-methoxy-5,7-dinitroindolin-1-yl)ethan-1-one trifluoroacetate
  • Molecular formula: C13H13N4O8F3
  • MW: 410.24 Da
  • Standard packaging size: 12,5 mg (custom packaging available 6 mg -20 mg)
Benefits
    • Rapidly and efficiently releases Gly (Glycine) neurotransmitter, by the effect of one (360 nm) or two photon (720 nm) irradiation
    • Glycine is an inhibitory neurotransmitter on GlyR in the CNS, especially in the spinal cord, brainstem, and retina, via ionotropic receptors, causing an Inhibitory postsynaptic potential (IPSP)
    • Exists as trifluoroacetic acid salted form, ensuring good solubility, stability and low hygroscopicity of the product
    • Highly resistant to hydrolysis at neutral pH
    • High quantum yield

 

GET A QUOTE

 

References

Molecular structure and function of the glycine receptor chloride channel.
Lynch, J. W., Physiological Reviews (2004)

Provided by

DNI-NMDA*TFA

Technology Overview

Femtonics Chemistry designs and develops new caged neurotransmitters for frontier neuroscience research. The two main products are a glutamate derivative and a GABA (gamma-amino-butyric acid) derivative. These dinitro-indoline-masked forms of glutamate and GABA release the bioactive forms of the two neurotransmitters more rapidly than other, commercially available versions of these compounds. They were developed to have high-quantum yield, requiring less irradiation for release, so their effective concentrations are lower than that of other caging scaffolds. DNI-Glu and iDMPO-DNI-GABA are compounds developed in-house, only available from Femtonics; in addition, iDMPO-DNI-GABA is the only commercially available caged GABA compound.

Features
  • Name: 4-methoxy-5,7-dinitroindolinyl-N-methyl-D-aspartate trifluoroacetate
  • Molecular formula: C16H17N4O10F3
  • MW: 482.32 Da
  • Standard packaging size: 6 mg (custom packaging available 14 mg or 20 mg )
Benefits
    • Rapidly and efficiently releases NMDA (N-methyl-D-Asp) neurotransmitter (selective NMDAR agonist), by the effect of one (360 nm) or two photon (720 nm) irradiation
    • Exists as trifluoroacetic acid salted form, ensuring good solubility, stability and low hygroscopicity of the product
    • Highly resistant to hydrolysis at neutral pH
    • Higher quantum yield (ca. 7 times, than MNI-NMDA)
    • Releases NMDA neurotransmitter more rapidly by the effect of two photon irradiation (720 nm) than MNI-NMDA

 

GET A QUOTE

 

References

Stereotyped initiation of retinal waves by bipolar cells via presynaptic NMDA autoreceptors.
Zhang, R. W. et al.  Nat. Commun. (2016)

New caged neurotransmitter analogs selective for glutamate receptor sub-types based on methoxynitroindoline and nitrophenylethoxycarbonyl caging groups.
Palma-Cerda, F. et al. Neuropharmacology (2012)

 

Provided by

iDMPO-DNI-GABA*TFA

Technology Overview

Femtonics Chemistry designs and develops new caged neurotransmitters for frontier neuroscience research. The two main products are a glutamate derivative and a GABA (gamma-amino-butyric acid) derivative. These dinitro-indoline-masked forms of glutamate and GABA release the bioactive forms of the two neurotransmitters more rapidly than other, commercially available versions of these compounds. They were developed to have high-quantum yield, requiring less irradiation for release, so their effective concentrations are lower than that of other caging scaffolds. DNI-Glu and iDMPO-DNI-GABA are compounds developed in-house, only available from Femtonics; in addition, iDMPO-DNI-GABA is the only commercially available caged GABA compound.

Features
  • Name: 4-aminoalkyl-5,7-dinitroindolinyl-GABA trifluoroacetate
  • Molecular formula: C21H27N5O10F6
  • MW: 623.50 Da
  • Standard packaging size: 19 mg (custom packaging available 6 mg -20 mg)
Benefits
    • Rapidly and efficiently releases GABA (γ-aminobutyric acid) neurotransmitter, by the effect of one (360 nm) or two photon (720 nm) irradiation
    • GABA is the chief inhibitory neurotransmitter in the mammalian central nervous system. Its principal role is reducing neuronal excitability throughout the nervous system
    • Exists as trifluoroacetic acid salted form, ensuring good solubility, stability and low hygroscopicity of the product
    • Highly resistant to hydrolysis at neutral pH
    • High quantum yield

 

GET A QUOTE

 

References

Theoretical Design, Synthesis, and In Vitro Neurobiological Applications of a Highly Efficient Two-Photon Caged GABA Validated on an Epileptic Case.
Chiovini, B. et al. ACS Omega (2021)

Disruption of centrifugal inhibition to olfactory bulb granule cells impairs olfactory discrimination.
Nunez-Parra, A. et al. PLoS One (2013)

Presynaptic miniature GABAergic currents in developing interneurons.
Trigo, F. F. et al. Neuron (2010)

Laser photolysis of DPNI-GABA, a tool for investigating the properties and distribution of GABA receptors and for silencing neurons in situ.
Trigo, F. F. et al. J.Neurosci.Meths. (2009)

GABA and GABA receptors in the central nervous system and other organs.
Watanabe, M. et al. Int. Rev. Cytol. (2002)

Provided by

DNI-D-Asp*TFA

Technology Overview

Femtonics Chemistry designs and develops new caged neurotransmitters for frontier neuroscience research. The two main products are a glutamate derivative and a GABA (gamma-amino-butyric acid) derivative. These dinitro-indoline-masked forms of glutamate and GABA release the bioactive forms of the two neurotransmitters more rapidly than other, commercially available versions of these compounds. They were developed to have high-quantum yield, requiring less irradiation for release, so their effective concentrations are lower than that of other caging scaffolds. DNI-Glu and iDMPO-DNI-GABA are compounds developed in-house, only available from Femtonics; in addition, iDMPO-DNI-GABA is the only commercially available caged GABA compound.

Features
  • Name: 4-methoxy-5,7-dinitroindolinyl-D-aspartate trifluoroacetate
  • Molecular formula: C15H15N4O10F3
  • MW: 468.30 Da
  • Standard packaging size: 6 mg (custom packaging available 14 mg or 20 mg)
Benefits
    • Rapidly and efficiently releases D-Asp neurotransmitter, by the effect of one (360 nm) or two photon (720 nm) irradiation
    • Agonist at NMDA receptors and EAAT substrate
    • Exists as trifluoroacetic acid salted form, ensuring good solubility, stability and low hygroscopicity of the product
    • Highly resistant to hydrolysis at neutral pH
    • Higher quantum yield (ca. 7 times, than MNI-D-Asp)
    • Releases D-Asp neurotransmitter more rapidly by the effect of two photon irradiation (720 nm) than MNI-D-Asp

 

GET A QUOTE

 

References

Synthesis and characterization of 4-methoxy-7-nitroindolinyl-D-aspartate, a caged compound for selective activation of glutamate transporters and N-MthD.-aspartate receptors in brain tissue.
Huang, Y. H. et al. Biochemistry (2005)